Fifty years of treating the vascular wall as a closed system has left us with a fairly embarrassing level of reductionism. We fixate on LDL and CRP as the primary drivers of plaque, but it’s like trying to solve a crisis by firing the middle managers while the CEO—the microbiome—is busy signing orders to destabilize the fibrous caps.

This isn't some supporting role. It's direct authority.

We outsourced our immune calibration and metabolic signaling to these commensals half a billion years ago because it was efficient, and now we're paying the interest on that debt. The gut doesn’t just influence the heart; it sets the basal inflammatory tone for the entire macrophage population. Whether a plaque calcifies into a stable scar or necrotizes into a lethal rupture often depends on a metabolic briefing from the distal colon, not the cell nucleus.

The hard truth is that we don't have a clue how to renegotiate this contract.

We can map every SNP in the human genome, yet we’re still functionally illiterate when it comes to the inter-kingdom signaling that dictates why one person’s macrophages can clear cholesterol and another’s simply undergo programmed cell death. We don't know why a specific microbial metabolite stabilizes a lesion in one patient but triggers an inflammatory cascade in another. We're missing the Rosetta Stone for host-microbe signaling.

If we want to stop managing cardiovascular decay and actually reverse it, we have to stop treating the microbiome as a lifestyle factor and start treating it as a primary organ of the vascular system.

We need massive, longitudinal funding for the "Metabolic Handshake"—the specific point where microbial waste becomes an executive signal for the human immune system. I’m looking for collaborators who are ready to move past simple diversity metrics and start mapping the actual orders these microbes send to our arteries. If we don’t solve this, every longevity intervention we design is just a suggestion that the parallel government is free to veto.